A Study of LY3023414 in Japanese Participants With Advanced Cancer
A Phase 1 Study of LY3023414 in Japanese Patients With Advanced Malignancies
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Chiba, Japan, 277 8577
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
-
Tokyo, Japan, 104-0045,
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria
- Have histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic and must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed or for whom standard therapy would not be appropriate.
- Have the presence of measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Have adequate organ and coagulation function.
- Have discontinued all previous cancer therapies, and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 half-lives prior to study treatment, whichever is shorter, and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy for at least 42 days.
- Are able to swallow capsules.
- Males must agree to use medically approved barrier contraceptive precautions during the study and for 3 months following the last dose of study drug.
- Females with childbearing potential: Must agree to use medically approved contraceptive precautions during the study and for 3 months following the last dose of study drug, must have had a negative serum or urine pregnancy test ≤7 days before the first dose of study drug.
- A breastfeeding woman must not be breastfeeding. If a female who stops breastfeeding enters the study, breastfeeding must cease from the day of the first study drug administration until at least 3 months after the last administration.
Exclusion Criteria
- Have serious pre-existing medical conditions.
- Have symptomatic central nervous system malignancy or metastasis.
- Have known acute or chronic leukemia or current hematologic malignancies that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
- Have a known active fungal, bacterial, and/or known viral infection.
- Intolerance to any previous treatment with any phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitor. Treatment with any PI3K/AKT/mTOR inhibitor must have discontinued for at least 21 days or 5 half-lives prior to first study drug administration, whichever is shorter, and participants must have recovered from the acute effects of therapy.
- Have a second primary malignancy that, in the judgment of the investigator, and sponsor may affect the interpretation of results.
- Participants with active alcohol abuse, as determined by the investigator.
- Have a history of heart failure according to New York Heart Association Class ≥3.
- Have corrected QT (QTc) interval of >470 milliseconds (msec) on screening electrocardiogram (ECG).
- Have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus.
- Have any evidence of clinically active interstitial lung disease (ILD).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: LY3023414
LY3023414 administered orally, twice daily in 21-day cycles.
Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
|
LY3023414 administered orally.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of Participants with LY3023414 Dose-Limiting Toxicities (DLT)
Tidsramme: Cycle 1 (21 days)
|
Cycle 1 (21 days)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve (AUC) of LY3023414
Tidsramme: Predose Cycle 1 through predose Cycle 3. (Cycle = 21 days.)
|
Predose Cycle 1 through predose Cycle 3. (Cycle = 21 days.)
|
|
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3023414
Tidsramme: Predose Cycle 1 through predose Cycle 3. (Cycle = 21 days.)
|
Predose Cycle 1 through predose Cycle 3. (Cycle = 21 days.)
|
|
Proportion of Participants With Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])
Tidsramme: Baseline through study completion (estimated as up to five months)
|
Baseline through study completion (estimated as up to five months)
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
Andre studie-ID-numre
- 15838
- I6A-JE-CBBH (Annen identifikator: Eli Lilly and Company)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .